5 questions answered from cited research · Plain language
Clarithromycin resistance significantly lowers H. pylori eradication success in children, but bismuth-based quadruple therapy or tailored regimens can overcome this resistance.
Read the full answer →In children aged 4–13 years, studies compare triple therapy (PPI + amoxicillin + clarithromycin or PPI + metronidazole + clarithromycin) versus bismuth-containing quadruple therapy (adding bismuth).
Read the full answer →Yes, a 2025 meta-analysis found vonoprazan-based therapies achieve 94% eradication in Asian patients, but real-world rates vary.
Read the full answer →Yes, a monoclonal stool antigen test is a reliable non-invasive tool for detecting H. pylori in chronic atrophic gastritis, with high specificity and strong diagnostic consistency.
Read the full answer →Yes, bismuth quadruple therapy works better than triple therapy for H. pylori eradication in children, with higher success rates especially when clarithromycin resistance is present.
Read the full answer →